Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants

被引:0
|
作者
Alessandra Zanetti [1 ]
Francesca D’Avanzo [2 ]
Rosella Tomanin [1 ]
机构
[1] Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children’s Health, University of Padova, Padova
[2] Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova
关键词
Enzyme replacement therapy; Hunter syndrome; IDS; IDS variants; IDSP1; Iduronate; 2-sulfatase; Lysosomal storage disorder; MPS II; Mucopolysaccharidosis type II; Recombination; Variants classification;
D O I
10.1186/s40246-024-00701-w
中图分类号
学科分类号
摘要
Purpose: Mucopolysaccharidosis type II (MPS II) is a rare X-linked lysosomal storage disorder caused by genetic alterations in the iduronate 2-sulfatase (IDS) gene. A wide range of variants has been reported for different countries and ethnic groups. We collected, analyzed and uniformly summarized all published IDS gene variants reported in literature up to June 2023, here providing the first worldwide review and classification. Methods: Data was obtained from a literature search, conducted in PubMed and Google. All data was analyzed to define the most common alleles, geographic distribution and genotype-phenotype correlation. Moreover, point variants were classified according to their pathogenicity, based on the ACMG guidelines. Results: Several types of variants have been described in the IDS gene, including intrachromosomal homologous recombination occurring between the homologous regions of IDS gene and its pseudogene IDSP1. Overall, we collected 2852 individuals from 2798 families, including 24 female patients. Most families carried missense variants, followed by large deletions-insertions and complex rearrangements, small frameshift deletions/insertions and nonsense variants. Based on ACMG guidelines, 62.9% of the 779 point variants were classified as “pathogenic”, 35.4% as “likely pathogenic”, and the remaining 13 variants as having “uncertain significance”. Conclusion: Data from this study confirmed that MPS II is a genetically very heterogeneous disorder, making genotype-phenotype correlation very challenging and in most cases merely unfeasible. Mutation updates are essential for the correct molecular diagnosis, genetic counseling, prenatal and preimplantation diagnosis, and disease management. © The Author(s) 2024.
引用
收藏
相关论文
共 50 条
  • [41] Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
    da Silva, Edina M. K.
    Louzada Strufaldi, Maria Wany
    Andriolo, Regis B.
    Silva, Laercio A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [42] CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)
    Motas, Sandra
    Haurigot, Virginia
    Garcia, Miguel
    Marco, Sara
    Ribera, Albert
    Roca, Carles
    Sanchez, Xavier
    Sanchez, Vctor
    Molas, Maria
    Bertolin, Joan
    Maggioni, Luca
    Leon, Xavier
    Ruberte, Jesus
    Bosch, Fatima
    JCI INSIGHT, 2016, 1 (09):
  • [43] Genetic analysis of 63 Chinese patients with mucopolysaccharidosis type II: Functional characterization of seven novel IDS variants
    Zhang, Wen
    Xie, Ting
    Sheng, Huiying
    Shao, Yongxian
    Lin, Yunting
    Jiang, Minyan
    Xu, Aijing
    Su, Xueying
    Liu, Zongcai
    Zhao, Xiaoyuan
    Liu, Li
    Huang, Yonglan
    CLINICA CHIMICA ACTA, 2019, 491 : 114 - 120
  • [44] High Prevalence of Carpal Tunnel Syndrome in Children With Mucopolysaccharidosis Type II (Hunter Syndrome)
    Kwon, Jeong-Yi
    Ko, Kiljun
    Sohn, Young Bae
    Kim, Su Jin
    Park, Sung Won
    Kim, Se-Hwa
    Cho, Sung-Yoon
    Jin, Dong-Kyu
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2011, 155A (06) : 1329 - 1335
  • [45] Clinical and morphologic features of mucopolysaccharidosis type II in a dog: Naturally occurring model of Hunter syndrome
    Wilkerson, MJ
    Lewis, DC
    Marks, SL
    Prieur, DJ
    VETERINARY PATHOLOGY, 1998, 35 (03) : 230 - 233
  • [46] Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome)
    Papadia, F.
    Lozupone, M. S.
    Gaeta, A.
    Capodiferro, D.
    Lacalendola, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2011, 15 (03) : 253 - 258
  • [47] Association between brain structural anomalies, electroencephalogram and history of seizures in Mucopolysaccharidosis type II (Hunter syndrome)
    Ramón Ernesto Jiménez-Arredondo
    Aniel Jessica Leticia Brambila-Tapia
    Francisco Miguel Mercado-Silva
    Martha Ortiz-Aranda
    Verónica Benites-Godinez
    Graciela Olmos-García-de-ALBA
    Luis Eduardo Figuera
    Neurological Sciences, 2017, 38 : 445 - 450
  • [48] Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
    Cho, Sung Yoon
    Huh, Rimm
    Chang, Mi Sun
    Lee, Jieun
    Kwun, Younghee
    Maeng, Se Hyun
    Kim, Su Jin
    Sohn, Young Bae
    Park, Sung Won
    Kwon, Eun-Kyung
    Han, Sun Ju
    Jung, Jooyoun
    Jin, Dong-Kyu
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (02) : 254 - 260
  • [49] Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
    Whiteman, David A. H.
    Kimura, Alan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2467 - 2480
  • [50] Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan
    Hattori, Yusuke
    Sawada, Takaaki
    Kido, Jun
    Sugawara, Keishin
    Yoshida, Shinichiro
    Matsumoto, Shirou
    Inoue, Takahito
    Hirose, Shinichi
    Nakamura, Kimitoshi
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2023, 37